Funding
Growth financing · Biotech

Primrose Bio secures growth financing led by Signet Healthcare Partners

The capital will support wider adoption of its biologics manufacturing technologies.

By RoundOS Funding desk

Primrose Bio has secured an undisclosed amount of growth capital led by Signet Healthcare Partners. Existing investors 1315 Capital, Agent Capital, LDV Partners and Ligand Pharmaceuticals also backed the financing.

The company supplies technologies for producing biologic drugs, mRNA products and vaccines. Signet’s founding managing partner James Gale will join its board as Primrose expands its manufacturing capabilities and commercial adoption.

Use of funds

Expand manufacturing technology adoption and capabilities

Funding history

Growth financing · This roundUndisclosed

Sources

  1. Financing announcementprimrosebio.com · Sep 22, 2026

Similar rounds

All Biotech rounds →
Estuary Biotherapeutics

Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.

$93MSeries A · Oct 16, 2026
OMass Therapeutics

OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.

$310MSeries C · Oct 15, 2026
Undecimal Bio

Undecimal Bio develops delivery molecules that help RNA medicines reach specific tissues, with initial research programmes in kidney and vascular disease.

$18MSeed · Oct 13, 2026
Soufflé Therapeutics

Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.

$135MSeries B · Oct 13, 2026

Related